Or­biMed forms biotech with as­sets from Chi­na-based Keymed, en­lists for­mer Bio­haven ex­ec as CEO

Or­biMed, a long­time biotech fun­der, cre­at­ed a start­up with two bis­pe­cif­ic an­ti­bod­ies li­censed from a drug­mak­er in Chi­na and put a for­mer Bio­haven ex­ec­u­tive at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER